Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder

CompletedOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

June 1, 2017

Study Completion Date

August 31, 2017

Conditions
Death
Interventions
DEVICE

Hemostatic powder

HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.

Trial Locations (1)

10400

King chulalongkorn memorial hospita, Bangkok

All Listed Sponsors
collaborator

McGill University

OTHER

lead

King Chulalongkorn Memorial Hospital

OTHER

NCT03066700 - Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder | Biotech Hunter | Biotech Hunter